Cardiac stress test abnormal and Mobility decreased

Summary:

Mobility decreased is found among people with Cardiac stress test abnormal, especially for people who are female, 40-49 old.

The study analyzes which people have Mobility decreased with Cardiac stress test abnormal. It is created by eHealthMe based on reports of 11 people who have Cardiac stress test abnormal from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Cardiac stress test abnormal?

Cardiac stress test abnormal is found to be associated with 270 drugs and 368 conditions by eHealthMe. Check the latest studies of Cardiac stress test abnormal.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,778 drugs and 1,632 conditions by eHealthMe. Check the latest studies of Mobility decreased.



On Jul, 07, 2026

11 people who have Cardiac Stress Test Abnormal and Mobility Decreased are studied.

Would you have Mobility decreased when you have Cardiac stress test abnormal?

Gender of people who have Cardiac Stress Test Abnormal and experienced Mobility Decreased *:

  • female: 90.91 %
  • male: 9.09 %

Age of people who have Cardiac Stress Test Abnormal and experienced Mobility Decreased *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 54.55 %
  • 50-59: 0.0 %
  • 60+: 45.45 %

Common co-existing conditions for these people *:

  1. Stress And Anxiety: 9 people, 81.82%
  2. Insomnia (sleeplessness): 6 people, 54.55%
  3. Cardiac Disorder: 6 people, 54.55%
  4. Fatigue (feeling of tiredness): 6 people, 54.55%
  5. High Blood Cholesterol: 6 people, 54.55%
  6. Arthritis (form of joint disorder that involves inflammation of one or more joints): 6 people, 54.55%
  7. Restless Leg Syndrome (a powerful urge to move your legs): 6 people, 54.55%
  8. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 45.45%
  9. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 36.36%
  10. Musculoskeletal Chest Pain (pain in chest muscle or nerve or bones): 3 people, 27.27%

Common drugs taken by these people *:

  1. Methotrexate: 6 people, 54.55%
  2. Omeprazole: 6 people, 54.55%
  3. Regadenoson: 4 people, 36.36%
  4. Acetaminophen: 3 people, 27.27%
  5. Desyrel: 3 people, 27.27%
  6. Lotrel: 3 people, 27.27%
  7. Zoloft: 3 people, 27.27%
  8. Pantoprazole: 3 people, 27.27%
  9. Premarin: 3 people, 27.27%
  10. Ampyra: 3 people, 27.27%

Common symptoms for these people *:

  1. Fatigue (feeling of tiredness): 10 people, 90.91%
  2. Dizziness: 8 people, 72.73%
  3. Hypoaesthesia (reduced sense of touch or sensation): 7 people, 63.64%
  4. High Blood Pressure: 7 people, 63.64%
  5. Fainting (loss of consciousness and postural tone): 7 people, 63.64%
  6. Silent Myocardial Infarction (a heart attack without having any symptoms): 6 people, 54.55%
  7. Headache (pain in head): 6 people, 54.55%
  8. Heart Attack: 6 people, 54.55%
  9. Chest Pain: 6 people, 54.55%
  10. Depressed Mood: 5 people, 45.45%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition


Related studies:

Treatments, associated drugs and conditions:

All the drugs that are associated with Mobility decreased:

All the conditions that are associated with Mobility decreased:


How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Mobility decreased and Cardiac stress test abnormal, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: